Trials Today

Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis

Purpose

This is a randomized, placebo-controlled, double-blind, 6-month study followed by a 6-month open-label extension phase to evaluate the efficacy, safety, and tolerability of MN-001 in moderate to severe IPF patients. MN-001 or matching placebo were orally administered twice daily over a 26-week period in subjects with a confirmed diagnosis of IPF. A total of 15 subjects were enrolled.

Conditions

Idiopathic Pulmonary Fibrosis
IPF

Eligibility

Eligible Ages: Between 21 Years and 80 Years
Eligible Sex: All
Accepts Healthy Volunteers: No

Inclusion Criteria

Male or female subjects ages 21 to 80, inclusive - Presence of IPF confirmed per ATS criteria (2011) - Presence of moderate to severe disease, stage II-III defined by GAP index (Gender, Age and Physiology) - Subjects who are currently treated with OFEV™/Nintedanib should be on a stable dose for at least 3 months prior to initiation of the study drug. - Females of child-bearing potential must have a negative serum ß-hCG (human chorionic gonadotropin) at screening and must be willing to use appropriate contraception (as defined by the investigator) for the duration of study treatment and 30 days after the last dose of study treatment. - Males should practice contraception for the duration of study treatment and 30 days after the last dose of study treatment as follows: condom use and contraception by female partner. - Subject is in stable condition on the basis of medical history, physical examination, and laboratory screening, as determined by the investigator. - Subject is willing and able to comply with the protocol assessments and visits, in the opinion of the study nurse/coordinator and the Investigator. - Written informed consent is obtained prior to participating the study.

Exclusion Criteria

Expected to receive a lung transplant within 1 year from the start of the Treatment Phase or on a lung transplant waiting list at the start of the Treatment Phase. - Known explanation for interstitial lung disease - Subjects on OFEV™/Nintedanib with a dose interruption due to significant adverse events within 6 weeks of screening visits. - Ongoing IPF treatments with investigational therapy - Ongoing IPF treatments with Esbriet® (Pirfenidone) - Immunosuppressants (i.e., Mycophenolate, Imuran, Cyclophosphamide), and cytokine modulating agents within 1 month of Screening Visit and throughout the study - Use of antibiotics and systemic steroids due to IPF exacerbation within 1 month of Screening Visit - Clinically significant cardiovascular disease, including myocardial infarct within last 6 months, unstable ischemic heart disease, congestive heart failure or angina - Resting pulse < 50 bpm, SA (sinoatrial) or AV (atrioventricular) block, uncontrolled hypertension, or QTcF (QT interval corrected using the Fridericia formula) > 450 ms - Immune system disease - Any significant laboratory abnormality which, in the opinion of the Investigator, may put the subject at risk - History of malignancy < 5 years prior to signing the informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. - History or evidence of drug or alcohol abuse - History of HIV (human immunodeficiency virus) or other active infection. - Currently has a clinically significant medical condition including the following: neurological, psychiatric, immunological, metabolic, hepatic, hematological, pulmonary (other than IPF) , cardiovascular (including uncontrolled hypertension), gastrointestinal, urological disorder, or central nervous system (CNS) infection that would pose a risk to the subject if they were to participate in the study or that might confound the results of the study. Note: Active medical conditions that are minor or well-controlled are not exclusionary if, in the judgment of the Investigator, they do not affect risk to the subject or the study results. In cases in which the impact of the condition upon risk to the subject or study results is unclear, the Medical Monitor should be consulted. - CYP2C8 (cytochrome P450 isoenzyme C28) and CYP2C9 (cytochrome P450 isoenzyme C29) substrates with narrow therapeutic indices (i.e. paclitaxel, phenytoin and S-warfarin) within 14 days of Screening Visit and throughout the study. - Beta blockers within 14 days of Screening Visit and throughout the study - Macrolide or quinolone class antibiotics within 14 days of Screening Visit and throughout the study. - Poor peripheral venous access that will limit the ability to draw blood as judged by the Investigator. - Currently participating, or has participated in, a study with an investigational or marketed compound or device within 3 months prior to signing the informed consent. - Unwilling or unable to conduct Spirometry (Vital Capacity) test. - Unable to cooperate with any study procedures, unlikely to adhere to the study procedures and keep appointments, in the opinion of the Investigator, or is planning to relocate during the study.

Study Design

Phase: Phase 2
Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

Arm	Description	Assigned Intervention
Experimental Double-blind MN-001	MN-001 (tipelukast) 750 mg tablet by mouth twice daily for 26 weeks.	Drug: MN-001 A novel, orally bioavailable small molecule compound that demonstrates anti-inflammatory and anti-fibrotic activity Other names: Tipelukast
Placebo Comparator Double-blind Placebo	Matching placebo twice a day for 26 weeks.	Drug: Matching Placebo Excipients of MN-001/tipelukast Other names: placebo
Experimental Open-Label MN-001	All subjects who completed the DBT period were eligible to receive MN-001 (tipelukast) 750 mg tablets by mouth twice daily for 26 weeks.	Drug: MN-001 A novel, orally bioavailable small molecule compound that demonstrates anti-inflammatory and anti-fibrotic activity Other names: Tipelukast

Recruiting Locations

More Details

NCT ID: NCT02503657
Status: Completed
Sponsor: MediciNova

Detailed Description

This study was a single-center, randomized (2:1), placebo-controlled, double-blind, 6-month study followed by a 6-month open-label extension (OLE) phase in patients with moderate to severe IPF. Major inclusion criteria: physician diagnosed IPF (ATS Guidelines, 2011), males and females aged 21 to 80 years, GAP Stage II-III; on no anti-fibrotic treatment. Patients on stable dose of nintedanib for at least 3 months prior to the study were allowed. The study consisted of a Screening Phase (up to 3 months prior to Day1), a 26- week Double-Blind Treatment (DBT) period, followed by a 26-week Open-Label Extension (OLE) period, and a Follow-up / End of Study Visit (within 4 weeks of the last dose taken). A total of 15 patients were enrolled in the study. During the DBT period, participants were randomly assigned to receive MN-001 750 mg twice daily or a matching placebo in a 2:1 ratio (MN-001: placebo) for 26 weeks. During the OLE period, all participants received MN-001 750 mg twice daily for 26 weeks. Taken together, participants (n=15) received either MN-001 50 mg twice daily for 12 months (MN-001/MN-001) or matching placebo for 6 months and MN-001 750 mg twice daily for 6 months (Placebo/MN-001).

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.